By: IPP Bureau
Last updated : January 16, 2026 9:18 am
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
Venus Remedies Limited, a global leader in fixed-dosage injectables, has received marketing authorization from Indonesian regulators for its combination antibiotic, Ceftazidime + Avibactam.
This landmark approval is the company's first anti-infective authorization in Indonesia and paves the way for the nation's first generic launch of this specific treatment. The achievement aligns with Venus Remedies’ strategy to scale its international operations and bolster its commercial presence throughout Southeast Asia.
This authorization strengthens Venus Remedies’ footprint in the ASEAN region, where it maintains a commercial presence in 10 countries and holds over 370 injectable approvals. The milestone supports the company’s mission to provide advanced critical-care therapies while reinforcing India’s reputation as a reliable provider of high-quality injectable pharmaceuticals to emerging global markets.
Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre, said, “The approval of Ceftazidime + Avibactam in Indonesia is an important regulatory milestone for Venus Remedies. It reflects our continued focus on addressing antimicrobial resistance through clinically relevant therapies designed for hospital-based care and reinforces our commitment to expanding access to life-saving anti-infective treatments in international markets.”
Ceftazidime + Avibactam is an advanced antibiotic combination indicated for the treatment of serious multidrug-resistant bacterial infections, including complicated intra-abdominal infections and complicated urinary tract infections caused by gram-negative pathogens such as Pseudomonas aeruginosa and Enterobacteriaceae. Avibactam inhibits key beta-lactamase enzymes, restoring the activity of ceftazidime against resistant strains and addressing a critical unmet need in the management of antimicrobial resistance.
Indonesia represents one of the largest pharmaceutical markets in Southeast Asia, with antibiotics forming a critical therapeutic segment due to the high burden of infectious diseases and increasing emphasis on antimicrobial stewardship. The broader ASEAN pharmaceutical market is projected to exceed USD 63.5 billion by 2029, highlighting the region’s growing strategic importance for India’s pharmaceutical exports and healthcare collaboration.
Aditi K. Chaudhary, President, International Business, Venus Remedies Limited, said, “With the approval of Ceftazidime + Avibactam, Venus Remedies enters the anti-infective segment in Indonesia, expanding beyond our existing presence in oncology. Indonesia is a priority market for us, and this milestone reflects our long-term commitment to building a compliant, scalable, and sustainable business in the region.”